Alcon (ALC) closed at $75.26 on November 18, 2026, up 1.6% from the previous close, on volume of 3,780,571 shares (30-day average 2,137,774).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Seagull Ratio With Put Spread | 20-Nov-2667.5 P : 70 P : 80[2x] C | 3,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Q3 13F roundup: Big bets on SpaceX, AI and major portfolio exits
Seeking Alpha News (Tue, 17-Nov 8:51 AM ET)
Quant ratings on Bill Ackman’s Pershing Square Q3 holdings: AMZN, MSFT, META, MA, V
Seeking Alpha News (Tue, 17-Nov 5:16 AM ET)
Pershing Square adds Alcon, increases Netflix, and exits Hertz, among Q3 moves
Seeking Alpha News (Mon, 16-Nov 5:39 PM ET)
Alcon leans on equipment launches and dry-eye demand as Q3 core EPS reaches $0.91
Market Chameleon (Tue, 10-Nov 12:48 PM ET)
Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth
Business Wire (Tue, 10-Nov 4:30 PM ET)
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Business Wire (Tue, 20-Oct 4:35 PM ET)
Business Wire (Fri, 16-Oct 3:57 PM ET)
Business Wire (Mon, 28-Sep 10:15 AM ET)
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Business Wire (Thu, 3-Sep 9:00 AM ET)
Alcon Prices EUR 500 Million Senior Notes Offering
Business Wire (Wed, 26-Aug 5:00 PM ET)
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Alcon trades on the NYSE stock market under the symbol ALC.
As of November 19, 2026, ALC stock price declined to $75.09 with 2,197,663 million shares trading.
ALC has a beta of 0.25, meaning it tends to be less sensitive to market movements. ALC has a correlation of 0.01 to the broad based SPY ETF.
ALC has a market cap of $37.14 billion. This is considered a Large Cap stock.
Last quarter Alcon reported $3 billion in Revenue and $.91 earnings per share. This fell short of revenue expectation by $-23 million and exceeded earnings estimates by $.02.
In the last 3 years, ALC traded as high as $101.10 and as low as $61.84.
The top ETF exchange traded funds that ALC belongs to (by Net Assets): EQTY, DFIV, DFAI, DFIC, DFAX.
ALC has underperformed the market in the last year with a return of -0.5%, while SPY returned +10.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ALC shares. However, ALC has outperformed the market in the last 3 month and 2 week periods, returning +2.1% and -2.9%, while SPY returned -5.7% and -5.9%, respectively. This indicates ALC has been having a stronger performance recently.
ALC support price is $73.86 and resistance is $76.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALC shares will trade within this expected range on the day.